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Cerebrovascular disease—advances
in management
Recent advances in the diagnosis and treatment of stroke have justified
its management as a medical emergency. This article summarises
current recommendations for the initial management of major types
of stroke with emphasis on acute therapy for ischaemic stroke. Recom-
mendations are based on the results of well-designed clinical trials.
An acute stroke care team and an acute stroke unit should be estab-
lished in all regional hospitals.
Diagnosis of stroke must be accurate. General management aims
for prevention and treatment of neurological and systemic complications,
whereas specific management varies according to the stroke type and
the underlying pathogenic mechanisms. For selected patients with is-
chaemic stroke, intravenous recombinant tissue plasminogen activator
or a modified viper venom within 3 hours of onset, or intra-arterial
pro-urokinase within 6 hours may improve functional outcomes. Neuro-
surgical treatment is indicated for some patients with ischaemic or
haemorrhagic strokes. Prevention of recurrence and rehabilitation are
the core components of subsequent management.
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Introduction
Stroke is not a cerebrovascular ‘accident’. It is a consequence of cerebro-
vascular disease and a leading cause of death and disability—approxi-
mately one third of stroke patients die and another third survive with
significant neurological deficits. Recently, there have been some break-
throughs in both diagnosis and treatment. Stroke should therefore be
managed as a brain-threatening emergency—a ‘brain attack’.
Stroke is defined as a syndrome with rapidly developing signs of focal
or global disturbance in cerebral or visual functions due to non-traumatic
vascular causes, with symptoms lasting for at least 24 hours, or having
a rapidly fatal course.1 The major pathological types of stroke are
HKMJ Vol 7 No 1 March 2001      59
Management of cerebrovascular disease
ischaemic stroke (ISS or cerebral infarction), intra-
cerebral haemorrhage (ICH or haemorrhagic stroke),
and subarachnoid haemorrhage (SAH). A transient
ischaemic attack (TIA) is essentially a mild ISS with
symptoms resolving within 24 hours, of which the
symptoms of most TIAs resolve in less than 1 hour.2
The artificial cutoff of 24 hours between strokes and
TIAs requires amendment because of the narrow time
window for acute interventions in ISS (within 6 hours
of onset). A TIA provides a warning of an increased
risk of stroke and warrants aggressive measures of
stroke prevention.2 The management of traditionally
defined TIA is identical to that of ISS.
Among Caucasians, ISS accounts for 80% to 85%
of all strokes, ICH accounts for 10% to 15% of strokes,
and the remaining 5% are due to SAH.3,4 Previous
local studies have reported different figures for the
Hong Kong population—specifically, 60% to 65% for
ISS and 30% to 35% for ICH.5,6  A recent local study,
however, found rates of ISS (78.3%), ICH (21.4%),
TIAs (5.2%), and SAHs (0.2%), which are more
similar to those found in Caucasians.7
Overall management of stroke is multifaceted and
includes primary prevention, management of acute
stroke, prevention and treatment of systemic or neuro-
logical complications, rehabilitation, and secondary
prevention. This article is a brief review of the initial
management of major types of stroke during the
first few days after onset, with emphasis on acute
therapy for ISS. Readers should refer to other articles
for discussions of aetiology and pathogenesis of
stroke and rehabilitation after stroke, as well as pri-
mary and secondary prevention of stroke.8,9 The rec-
ommendations reported herein are based on currently
available data from clinical trials. When evidence
is not available from clinical trials, consensus state-
ments from expert groups have been adopted as the
guidelines for treatment.
Initial evaluation
Stroke should be suspected in all patients presenting
with sudden onset of focal neurological symptoms and
signs, including:
(1) Weakness, paralysis, incoordination, and/or
sensory loss of the arm and/or leg;
(2) Facial weakness, asymmetry, and/or sensory loss;
(3) Dysarthria or aphasia;
(4) Monocular or binocular visual loss;
(5) Ataxia, poor balance, clumsiness, or difficulty in
walking;
(6) Vertigo, double vision, nausea, or vomiting; and
(7) Stupor or coma, confusion, agitation, or seizures.10
The pattern of deficits reflects the site of stroke
(Table 1). Differential diagnoses include cranio-cervical
trauma, focal seizures, drug intoxication, brain tumour,
encephalitis, brain abscess, subdural haematoma, hypo-
glycaemia, migraine with focal neurological symptoms,
and syncope. Clinical features alone cannot reliably
differentiate between ISS and ICH. Subarachnoid haem-
orrhage, however, may be preceded by some character-
istic clinical features (Box 1), which serve as warning
symptoms. Differential diagnoses also include migraine,
tension headache, meningitis, cervical spine injury or
arthritis, and whiplash injury.11
Management of stroke starts with an accurate diag-
nosis and classification of stroke types from studying
the history of patients, physical examination, and in-
vestigations.4,11,12 The general medical examination
should focus on the cardiovascular system. A complete
Table 1. Patterns of neurological deficit according to the location of stroke10
Location Pattern
Left (dominant) hemisphere Aphasia, right hemiparesis and/or sensory loss, right homonymous
hemianopsia, impaired conjugate gaze to right, dysarthria, dyslexia,
dysgraphia, dyscalculia
Right (non-dominant) hemisphere Left-sided visual-spatial neglect, left-sided weakness and/or sensory loss,
impaired conjugate gaze to left, dysarthria, spatial disorientation, apraxia
Brain stem, cerebellum, or Motor or sensory loss in all 4 limbs, cranial nerve deficits with or without limb
occipital lobe weakness and/or sensory loss on opposite side of body, dysarthria,
dysconjugate gaze, nystagmus, gait ataxia, amnesia, bilateral visual field defects
Small subcortical hemisphere or Pure motor stroke with weakness of face and limbs on the same side without
brain stem abnormalities of higher brain functions, sensation, or vision; pure sensory stroke
with reduced sensation of face and limbs without abnormalities of higher brain
functions, sensation, or vision; ataxia, hemiparesis; clumsy hand, dysarthria
Box 1. Characteristic presenting features of
subarachnoid haemorrhage
Sudden severe headache
Nausea and/or vomiting
Photophobia
Phonophobia
Neck stiffness
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neurological examination should be performed, includ-
ing the Glasgow Coma Scale, the National Institutes
of Health Stroke Scale (NIHSS) [Table 2], and the
Hunt and Hess Scale for suspected SAH (Box 2).4,11-13
The severity and nature of the neurological deficits
documented reveals the extent of ongoing brain injury
and forecasts the prognosis.
Admission to an acute stroke unit reduces the risk
of death, lessens disability, and lowers the need for
long-term institutionalised care.14,15 A stroke unit is a
geographically defined facility within a hospital that
specialises in caring for patients with stroke. In this
unit, cardiac and neurological monitoring should be
available, whereas the facility for invasive monitoring
is optional. Initial evaluation also includes assessment
of vital signs, estimation of the most likely aetiology,
and screening for any complications.
Initial investigations
The recommended initial investigations for stroke
are listed in Box 3.4 Early computed tomography (CT)
signs of ISS include loss of the insular ribbon, obscur-
ation of the lentiform nucleus, and cerebral hypo-
density or early sulcal effacement.4,11,12 The hyperdense
artery sign reveals the site of ongoing ischaemia.
Computed tomography signs of early infarction are
often associated with more serious ischaemic injury,
poor outcome, and a greater risk of haemorrhage trans-
formation.16,17 Magnetic resonance imaging (MRI) is
more sensitive than CT in detecting small subcortical
or cortical infarctions, or lesions in the posterior fossa.
The age of the haematoma can also be estimated by
MRI.4,12 Magnetic resonance imaging, however, has
some short-comings: it is not commonly available,
acute haemorrhage may be missed, and MRI cannot be
used for patients with claustrophobia, a pacemaker, or
metallic implants. Cerebral angiography, transcranial
Doppler, and duplex ultrasound examination of the
cervical arteries can be helpful for detecting arterial dis-
eases such as atherosclerosis and dissection.17 Trans-
thoracic and transoesophageal echocardiography and
Holter monitoring are similarly useful in screening for
cardiogenic embolism and aortic plaques.4 Special
haematological and serological tests are also indicated
Table 2. The National Institutes of Health Stroke Scale (abbreviated version)13
Item Score
Level of consciousness 0 (alert), 1 (arousable), 2 (obtunded), 3 (coma)
Orientation
two questions 0 (both correct), 1 (one correct), 2 (neither correct)
two commands 0 (both correct), 1 (one correct), 2 (neither correct)
Eye movements 0 (normal), 1 (partial), 2 (forced deviation or total gaze paresis)
Visual fields 0 (normal), 1 (partial), 2 (complete), 3 (bilateral hemianopsia)
Facial palsy 0 (normal), 1 (minor), 2 (partial), 3 (complete or bilateral)
Left arm motor 0 (no drift), 1 (drift), 2 (some effort against gravity), 3 (no effort against gravity),
4 (no movement)
Right arm motor 0 (no drift), 1 (drift), 2 (some effort against gravity), 3 (no effort against gravity),
4 (no movement)
Left leg motor 0 (no drift), 1 (drift), 2 (some effort against gravity), 3 (no effort against gravity),
4 (no movement)
Right leg motor 0 (no drift), 1 (drift), 2 (some effort against gravity), 3 (no effort against gravity),
4 (no movement)
Limb ataxia 0 (absent), 1 (one limb), 2 (two or more limbs)
Sensory 0 (normal), 1 (mild to moderate), 2 (severe or total sensory loss)
Language 0 (normal), 1 (mild to moderate), 2 (severe aphasia), 3 (mute)
Dysarthria 0 (normal), 1 (mild to moderate), 2 (severe)
Extinction or inattention 0 (absent), 1 (one modality), 2 (two or more modalities)
Box 2. Hunt and Hess Scale for subarachnoid
haemorrhage11
Grade 1 Asymptomatic or mild headache only
Grade 2 Moderate to severe headache
Nuchal rigidity
Oculomotor palsy
Grade 3 Confusion, drowsiness
Mild focal neurological signs
Grade 4 Stupor
Hemiparesis
Grade 5 Coma, moribund
Extensor posturing
Box 3. Recommended initial investigations for stroke4
Computed tomography of the brain without contrast
Electrocardiography
Chest X-rays
Complete blood count, prothrombin time, partial
 thromboplastin time, serum electrolytes, urea and
 creatinine, blood sugar, liver function tests
Fasting blood sugar and lipids
Arterial blood gas levels when hypoxia suspected*
Lumbar puncture for subarachnoid haemorrhage if
 computed tomography of the brain is inconclusive*
Cervical spine X-rays if patient is comatose or trauma is
 suspected*
Electroencephalography for seizures*
* Under certain other circumstances
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when hypercoagulability, antiphospholipid antibody
syndrome, or vasculitis are suspected.
General management
General management at the acute stage comprises
regular neurological observation and attention to vital
signs and potential complications (Table 3).4,11,12 Ad-
equate oxygen saturation is important. Hypoxia may
occur secondary to airway obstruction, hypoventilation,
aspiration pneumonia, and/or atelectasis. Hyperbaric
oxygen may be useful for some patients with stroke
secondary to an air embolism or Caisson’s disease.4
Corticosteroids are not recommended for cerebral oe-
dema or increased intracranial pressure (ICP).18,19 Osmo-
therapy (mannitol), hyperventilation, and neurosurgical
procedures are indicated in response to high ICP.4
Anticonvulsants should be prescribed to prevent
recurrent seizures in patients with ISS or ICH and
should be given to all patients with SAH during the
immediate post-haemorrhage period.4,11,12 An elevation
in blood pressure is commonly observed, however,
pharmacological treatment should be avoided unless
hypertension is severe (systolic pressure >220 mm Hg
in ISS, or mean pressure >130 mm Hg in ICH) or
thrombolytics are used.4,12,16 Since hyperthermia ag-
gravates brain damage, infection should be treated
vigorously, and hyperpyrexia should be controlled.4,20
Euglycaemia should also be maintained. Early mobil-
isation and low dose subcutaneous heparin can pre-
vent deep vein thrombosis and pulmonary embolism.4
Good nursing care, early physiotherapy, cautious
feeding, and adequate nutrition can all lower the risk
of subsequent medical complications.
Acute treatment of ischaemic stroke
An unstable ischaemic penumbra provides an oppor-
tunity for acute intervention within the therapeutic
time window.21 Four types of antithrombotics are avail-
able to treat thromboembolic occlusion of cerebral
vessels: plasminogen activators (thrombolytics), de-
fibrinogenation, anticoagulants, and antiplatelet agents.
Thrombolytic agents convert plasminogen to plasmin,
which cleaves fibrinogen and fibrin. Tissue plasmino-
gen activator , urokinase (UK) and pro-urokinase (pro-
UK) are ‘specific’ in binding selectively to the fibrin
clot, whereas streptokinase (SK) is ‘non-specific’ and
binds to both fibrin and fibrinogen.
Of the thrombolytics studied to date, only intra-
venous administration of recombinant tissue plasmino-
gen activator (rtPA) has been shown to be effective
in managing acute ISS, in terms of better functional
outcome and a trend towards reduced mortality.22-27
Specifically, the evidence indicates that one extra
patient will have an excellent functional outcome
for every eight patients receiving rtPA.22 The benefit
applies to different pathogenic subtypes of ischaemic
strokes and is sustained at 1 year poststroke.28,29 Table
4 summarises the inclusion and exclusion criteria
used in the National Institute of Neurological Dis-
orders and Stroke rtPA Stroke Study Group Trial.
The rtPA dose given was 0.9 mg/kg (with a maximum
90 mg) with 10% as a bolus dose and 90% infused
over 1 hour.
Heparin, warfarin, aspirin, or other antithrombotic
agents should be withheld for 24 hours after treatment
with rtPA. Nevertheless, intravenous rtPA treatment
Table 3. Common complications of stroke and recommended management4,11,12
Complications Management
Neurological
Cerebral oedema Hyperventilation, osmotherapy (mannitol)
Hydrocephalus Neurosurgical shunting
High intracranial pressure Hyperventilation, osmotherapy, neurosurgical monitoring
Haemorrhagic transformation Conservative, reverse bleeding tendency
Seizures Electroencephalography, anticonvulsants
Systemic
Aspiration Tube feeding, frequent suction
Hypoventilation Avoid sedatives, mechanical ventilation
Pneumonia Antibiotics, chest physiotherapy, oxygen
Myocardial ischaemia Avoid hypoxia, nitrates, consult cardiologist
Cardiac arrhythmias Avoid electrolyte disturbance, consult cardiologist
Deep vein thrombosis Subcutaneous heparin, early mobilisation
Pulmonary embolism Subcutaneous heparin, early mobilisation
Urinary tract infection Avoid indwelling catheter, antibiotics
Decubitus ulcers Regular turning, air mattress
Malnutrition Cautious oral feeding or tube feeding, parenteral nutrition
Contractures Early physiotherapy and mobilisation
Stiff joints Early physiotherapy and mobilisation
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carries a high (3% to 6%) risk of symptomatic haem-
orrhagic transformation (SHT),22,24,30 and mortality
rates of up to 60% within 6 weeks have been observed
in patients with SHT.22 Benefits associated with
rtPA use have not been seen when stroke patients were
treated between 3 and 6 hours after onset or when a
higher dose of rtPA was used.23,24,31 Factors associated
with a higher risk of SHT or a poor outcome include
increasing time from onset, uncontrolled hyper-
tension, a higher dose of rtPA, advanced age, severe
stroke (NIHSS >20), and early infarct signs on CT
scan.22,28
Future clinical trials are needed to determine the role
of SK in acute ISS. Studies to date indicate that intra-
venous SK produces unacceptable rates of SHT.25-27
Thrombolytic therapy—issues and options
Many stroke patients present to the hospital more
than 3 hours after onset. Only 3% to 4% of all stroke
patients are candidates for rtPA in the USA, for
example.32 In addition, only 1% of the National
Institute of Neurological Disorders and Stroke rtPA
Stroke Study Group Trial population were Asian by
race.22 Thus, the risk-benefit ratio of rtPA therapy is
uncertain in Asian populations. It is also unknown
whether Asian patients require an adjustment in dosage.
Although a local, randomised, placebo-controlled,
double-blinded clinical trial is needed to confirm the
efficacy and safety of rtPA in Hong Kong, it would be
difficult to conduct such a trial because only a small
percentage of patients are candidates for rtPA and
haemorrhagic stroke is relatively more common in Hong
Kong than in western countries.
Local intra-arterial infusion of a smaller dose of
thrombolytic agent is a logical alternative.16,33-36 There
are a number of theoretical advantages with this
approach. Firstly, the presence, site, and size of any
occluding thrombus or thromboembolus can be con-
firmed. Secondly, use of a lower dose would reduce
the risk of SHT. Thirdly, arterial recanalisation can
also be confirmed. Intra-arterial infusion would,
however, further delay thrombolysis since arterial
angiography is needed, adding extra risk to the patient.
Anecdotal case reports and uncontrolled studies on
local intra-arterial infusion of UK, pro-UK and rtPA
are available.16,33-36 A recently completed, randomised,
phase III clinical study of 180 patients (from screen-
ing of 12 000 patients) showed that 40% of patients
treated with pro-UK (9 mg infused over 2 hours) plus
low dose intravenous heparin (2000 IU bolus followed
by 500 IU/h for 4 hours) within 6 hours of a docu-
mented proximal middle cerebral artery (MCA) throm-
boembolic ISS had slight or no neurological disability
at 90 days, when compared to a rate of 25% in patients
treated with intravenous heparin alone. Futhermore,
pro-UK increased the rate of SHT from 2% to 10%,
whereas the mortality rate was unaffected.36 Intra-
arterial thrombolysis within 3 hours of onset remains
an experimental treatment option as it has not been
Table 4. Inclusion and exclusion criteria used in the National Institute of Neurological Disorders and Stroke rtPA
Stroke Study Group Trial22
Inclusion
Ischaemic stroke within 3 hours of onset
Measurable deficit on the National Institutes of Health Stroke Scale
No intracranial haemorrhage, tumour, aneurysm, arteriovenous malformation, nor early changes of a major cerebral
infarction on computed tomography of the brain
Exclusion
Pregnancy; minor
History of intracranial haemorrhage
Previous stroke or major head trauma within 3 months
Myocardial infarction within 3 months
Pericarditis within 6 weeks
Gastrointestinal bleeding or urinary tract haemorrhage within 3 weeks
Major surgery within 2 weeks
Arterial puncture at a non-compressible site within 1 week
Anticoagulated or received heparin within 2 days
Renal, liver, or other organ failure
Rapidly improving or minor symptoms
Symptoms of infarction of entire middle cerebral artery territory
Seizure at the onset of stroke
Complete loss of brain stem reflexes or coma
Features of subarachnoid haemorrhage
Systolic blood pressure >185 mm Hg or diastolic blood pressure >110 mm Hg
Elevated partial-thromboplastin time or prothrombin time
Platelet counts <100 000/mm3
Hypoglycaemia (<50 mg/dL) or hyperglycaemia (>400 mg/dL)
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shown to be more effective than intravenous rtPA
in improving clinical outcomes following ISS.16 Pa-
tients with stroke onset of between 3 and 6 hours
previously may benefit from intra-arterial pro-UK.36
Large, randomised, controlled clinical trials are needed
to clarify the role of intra-arterial thrombolysis.
Another option which allows extension of the treat-
ment time window beyond 3 hours is the ‘bridging’
technique of combining intravenous rtPA (at the lower
dose of 0.6 mg/kg) and intra-arterial rtPA.37
Queen Mary Hospital studies
Special triage of stroke patients potentially eligible
for acute thrombolysis and ongoing clinical trials on
neuroprotectants has been undertaken at the Queen
Mary Hospital accident and emergency department
since July 1998.38 Over a 30-month period, rtPA was
given to 10 eligible patients after informed written
consent was obtained from the patients and/or their
relatives. In addition, 17 patients were recruited into
ongoing clinical trials of neuroprotectants given within
6 hours of onset of stroke. Of seven patients treated
with intravenous rtPA (0.8 mg/kg), two patients with
severe deficits did not improve and died of massive
stroke. Haemorrhagic transformation was seen in one
of the two fatal cases. The remaining five patients
made an excellent or complete recovery from their
disabling stroke. All three patients treated with intra-
arterial rtPA (total dose, 11 to 21 mg) had haemorrhagic
transformation. This was asymptomatic for one pa-
tient who underwent a complete recovery. Transient
deterioraton with subsequent complete recovery was
seen in the second patient, after temporary ventricular
drainage for obstructive hydrocephalus, whereas no
improvement was seen in the third patient who suc-
cumbed to the massive MCA infarction. (Unpublished
data. RTF Cheung).
Acute defibrinogenation in ischaemic stroke
A recent placebo-controlled trial of acute defibrino-
genation involving 500 patients has been reported.
Acute defibrinogenation (to a target fibrinogen level
between 40 to 69 mg/dL) within 3 hours of stroke on-
set was achieved using intravenous infusion of ancrod,
a modified viper venom, for 5 days.39 A favourable
outcome was seen in 42% of the patients treated
with ancrod, compared with 34% of those treated with
placebo. Symptomatic haemorrhage transformation
was seen in 5.2% of the ancrod-treated patients com-
pared with 2% of controls, however. The benefit of
acute defibrinogenation in ISS remains to be confirmed
and compared against the efficacy of intravenous rtPA
in future studies.
Use of anticoagulants
Rapidly acting, parenteral anticoagulant agents may
stop clot propagation, prevent recurrent embolism and
help maintain perfusion to the ischaemic penumbra via
collaterals.4 The role of immediate or early anticoagu-
lation in acute cardioembolic stroke remains unknown.
Immediate anticoagulation carries an increased risk
of SHT. Spontaneous haemorrhagic transformation is
present in 30% to 40% of cardioembolic strokes, and
bleeding usually occurs within the first 2 to 4 days.40,41
In the International Stroke Trial, the benefit of early
antithrombotic treatment with aspirin (300 mg/day) or
two different doses of subcutaneous unfractionated
heparin (5000 or 12 500 IU twice daily) within 48 hours
of onset was assessed in patients with ISS.42 Neither
heparin regimen reduced the risk of death or level of
dependency at 6 months.
Subcutaneous low-molecular–weight heparin
(nadroparin) has been shown to be effective in pre-
venting deep vein thrombosis and pulmonary embol-
ism, whereas its benefit in ISS was suggested by the
results of a small clinical trial.43 In the first nadroparin
stroke study, the treatment window was within 48 hours
of onset. Elapsed time since awakening with symp-
toms was used for some patients however, and two
thirds of patients were given treatment 24 hours or more
after stroke onset.43 The second nadroparin stroke trial
was larger and better designed, using 24 hours post
stroke as the treatment window. Benefits seen in the
first study were  not confirmed, however.44 Similarly,
treatment with a low-molecular–weight heparinoid,
Org 10 172, did not confer a benefit for patients with
ISS.45 Further clinical trials are needed to determine
the efficacy of subcutaneous low-molecular–weight
heparins or heparinoids in ISS.46
For patients who need long-term anticoagulation
for secondary prevention of stroke, the optimum
time to commence treatment is uncertain. A popular
strategy is to delay anticoagulation for 48 hours
for small to moderate sized infarcts, and for 7 to 10
days for large infarcts.10 Computed tomography of
the brain should be repeated to exclude spontaneous
haemorrhagic transformation before initiation of
anticoagulation.
Antiplatelet agents
Antiplatelet agents (aspirin, aspirin plus dipyridamole,
ticlopidine, and clopidogrel) are effective for pro-
phylaxis against ischaemic events,4,9 and early use
of aspirin in ISS has been evaluated in two large
trials, the International Stroke Trial and the Chinese
Aspirin Stroke Trial.42,47 Early use of aspirin (160 to
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300 mg/day) within 48 hours of stroke onset could
reduce 11 cases of recurrent ISS or death per thousand
patients, and produce two additional cases of SHT.47
The glycoprotein IIb/IIIa receptor antagonists
are effective adjuncts for high-risk patients under-
going coronary angioplasty with or without stenting.
The Abciximab in Ischemic Stroke Investigators
reported encouraging results from a randomised,
double-blind, placebo-controlled, dose-escalation trial
involving 74 patients treated within 24 hours of onset.
Fifty four patients were treated with four escalating
doses of intravenous abciximab and 20 patients with
placebo.48 The scheduled post-study CT brain scans
detected asymptomatic parenchymal haemorrhages
in 7% of the abciximab-treated patients and 5% of the
placebo-treated patients. Another 11% of abciximab-
treated patients had asymptomatic parenchymal
haemorrhages on unscheduled brain imaging (CT or
MRI) performed between days 2 and 35. No instances
of SHT were noted. In contrast, however, a local study
using a similar dosing regimen was suspended when
one of the two Chinese patients died of SHT despite a
6-hour treatment window.49
Neuroprotectants
To date, none of the neuroprotectants—calcium chan-
nel blockers, inhibitors of glutamate release, glutamate
receptor antagonists, barbiturates, opiate antagonists,
free radical scavengers, or membrane active agents—
has been found to be beneficial following ISS.4,50
Results are still awaited from completed trials on
neuro-protectants, however, and other studies are
ongoing.51 There is no evidence to support the use of
haemodilution or volume expansion in ISS, and hypo-
thermia is currently an investigational treatment
modality.4
Neurosurgery
While surgical procedures to revascularise the ischae-
mic penumbra have not been shown to be effective in
controlled trials, there is now renewed interest in neuro-
surgical management (decompressive craniectomy or
infarctectomy) of malignant cerebral oedema due
to large hemispheric infarction.4,52 Monitoring of
ICP, drainage of hydrocephalus, and decompressive
posterior fossa surgery are considered appropriate
management in special circumstances.
Specific management of haemorrhagic strokes
The site of ICH is influenced by the underlying cause.3
In general, patients with ICH have greater deficits,
lower levels of consciousness, and greater increases
in ICP and blood pressure than patients with ISS. Close
neurological observation is crucial. Severely elevated
blood pressure should be treated to stop further
bleeding and recurrent bleeding. Medical and neuro-
surgical therapies can control raised ICP (Table 3).
Patients with a small ICH (<10 mL) or mild deficits,
and moribund patients with brainstem or hemispheric
haematoma should be treated medically.
Cerebellar haematoma should be surgically removed
in deteriorating patients with brainstem compression
or obstructive hydrocephalus.12 Surgical removal of
haematoma allows confirmation of the presence, as
well as management of underlying aneurysm, arterio-
venous malformation, or cavernous angioma in pa-
tients where the vascular lesion is accessible and there
is a good chance of recovery.12 Young patients with
a moderate or large lobar haematoma whose con-
dition is deteriorating, may be candidates for surgery.
Neurosurgery is currently not recommended for any
other patient groups pending more information from
clinical trials. Although bleeding diatheses are uncom-
mon causes of ICH, any bleeding tendency should
be promptly detected and corrected by appropriate
measures.3
Management of spontaneous subarachnoid
haemorrhage
Spontaneous SAH is due to rupture of a berry aneur-
ysm in most cases.11 The major causes of death and
disability include effects of the initial bleeding, recur-
rent SAH, and cerebral ischaemia due to vasospasm.
Neurosurgical input is crucial. Management is com-
plex and includes general and symptomatic treatment,
treatment of raised ICP and hydrocephalus, pre-
vention of recurrent SAH, and treatment of cerebral
ischaemia.11
The incidence of rebleeding peaks in the first
24 hours (occurring in approximately 4% of pa-
tients) and markedly decreases after the first 4
weeks.53 Rebleeding is preventable by clipping of
the an-eurysm. Other useful measures include con-
trol of blood pressure, use of antifibrinolytic agents,
and interventional neuroradiological procedures.11
The incidence of cerebral vasospasm peaks between
day 5 and day 14, with gradual resolution over 2
to 4 weeks.54 Adequate hydration, calcium antag-
onists (nimodipine 60 mg orally every 4 hours for
21 days), transluminal angioplasty, hypervolaemic
haemodilution, and induced hypertension (after
aneurysm clipping) are effective measures for this
complication.11
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Conclusions
Effective treatments exist for major types of stroke,
and strokes are highly preventable. The term brain
attack emphasises that stroke requires management
as a medical emergency. Stroke services should be
organised, with formation of acute stroke care teams
and the establishment of acute stroke units. The public,
medical doctors, and health professionals need to know
more about stroke and should be educated to view
stroke as a medical emergency. Many people, however,
do not currently recognise the presentation of stroke
and/or know the best response to its occurrence.55,56
Specific management varies according to the type
of stroke and the underlying pathogenic causes. Close
monitoring of neurological state, attention to vital
signs, and prevention and treatment of neurological
and systemic complications is crucial in managing all
types of stroke, however.
The traditional definition of TIA is now obsolete
given the time window for treatment of ISS of 3 to 6
hours. Among appropriately selected patients with
ISS, intravenous rtPA or ancrod within 3 hours of
onset, or intra-arterial pro-UK within 6 hours improves
functional outcomes. Early use of aspirin in ISS has a
small benefit. Advanced neuroimaging techniques
may further improve patient selection and extend the
time window for treatment via direct visualisation of
the ischaemic penumbra.17 A combination of intra-
venous and intra-arterial thrombolysis or combining
neuro-protective therapy with thrombolysis may
also extend the time window for treatment beyond
the current 3- to 6- hour limit.
New medical or surgical treatment for different
types of stroke will emerge from the results of large
randomised trials. Non-acute management of stroke
should be focused upon prevention of recurrent stroke
as well as rehabilitation of the patient with stroke.
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